Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 8, 2013, Pages 641-651

  Yamaguchi, Masayuki ^a   Saji, Takami ^a   Mita, Sachiko ^a   Kulmatycki, Kenneth ^b   He, Yan Ling ^b   Furihata, Kenichi ^c   Sekiguchi, Kaneo ^a  

^a NOVARTIS PHARMA K K   (Japan)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c P one Clinic Keikokai Medical Corporation   (Japan)

Author keywords

DPP 4; Japanese; Pharmacodynamics; Vildagliptin; Voglibose

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; VILDAGLIPTIN; VOGLIBOSE;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; JAPANESE; MALE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADAMANTANE; ADULT; ALPHA-GLUCOSIDASES; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG INTERACTIONS; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INOSITOL; INSULIN; MALE; MIDDLE AGED; NITRILES; PYRROLIDINES;

EID: 84883199049     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201902     Document Type: Article

References (32)

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011; 94: 311-321. CrossRef PubMed
2. Horikoshi M, Hara K, Ito C, Shojima N, Nagai R, Ueki K, Froguel P, Kadowaki T. Variations in the HHEX gene are associated with increased risk of type 2 diabetes in the Japanese population. Diabetologia. 2007; 50: 2461-2466. CrossRef PubMed
3. Sugimori H, Miyakawa M, Yoshida K, Izuno T, Takahashi E, Tanaka C, Nakamura K, Hinohara S. Health risk assessment for diabetes mellitus based on longitudinal analysis of MHTS database. J Med Syst. 1998; 22: 27-32. CrossRef PubMed
4. Omori S, Tanaka Y, Takahashi A, Hirose H, Kashiwagi A, Kaku K, Kawamori R, Nakamura Y, Maeda S. Association of CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11 with susceptibility to type 2 diabetes in a Japanese population. Diabetes. 2008; 57: 791- 795. CrossRef PubMed
5. Horikawa Y, Miyake K, Yasuda K, Enya M, Hirota Y, Yamagata K, Hinokio Y, Oka Y, Iwasaki N, Iwamoto Y, Yamada Y, Seino Y, Maegawa H, Kashiwagi A, Yamamoto K, Tokunaga K, Takeda J, Kasuga M. Replication of genome-wide association studies of type 2 diabetes susceptibility in Japan. J Clin Endocrinol Metab. 2008; 93: 3136-3141. CrossRef PubMed
6. Hirose T, Kawamori R. Diabetes in Japan. Curr Diab Rep. 2005; 5: 226-229. CrossRef PubMed
7. Deacon CF. Therapeutic strategies based on glucagon-like peptide 1. Diabetes. 2004; 53: 2181-2189. CrossRef PubMed
8. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes. 1998; 47: 1663-1670. CrossRef PubMed
9. Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin. 2007; 23: 919-931. CrossRef PubMed
10. Mentlein R. Dipeptidyl-peptidase IV (CD26)- role in the inactivation of regulatory peptides. Regul Pept. 1999; 85: 9-24. CrossRef PubMed
11. Lauster CD, McKaveney TP, Muench SV. Vildagliptin: a novel oral therapy for type 2 diabetes mellitus. Am J Health Syst Pharm. 2007; 64: 1265-1273. CrossRef PubMed
12. Ahrén B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab. 2011; 13: 775- 783. CrossRef PubMed
13. Stamataros G, Schneider SH. Vildagliptin in the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother. 2011; 12: 1967-1973. CrossRef PubMed
14. Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs. 2010; 70: 2089- 2112. CrossRef PubMed
15. Liu S-C, Tu Y-K, Chien M-N, Chien K-L. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab. 2012; 14: 810-820. CrossRef PubMed
16. He YL, Serra D, Wang Y, Campestrini J, Riviere GJ, Deacon CF, Holst JJ, Schwartz S, Nielsen JC, Ligueros-Saylan M. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2007; 46: 577-588. CrossRef PubMed
17. He YL, Yamaguchi M, Ito H, Terao S, Sekiguchi K. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes. Int J Clin Pharmacol Ther. 2010; 48: 582-595. PubMed
18. Chen X, Zheng Y, Shen Y. Voglibose (Basen, AO- 128), one of the most important alphaglucosidase inhibitors. Curr Med Chem. 2006; 13: 109-116. CrossRef PubMed
19. Seifarth C, Bergmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients. Diabet Med. 1998; 15: 485-491. CrossRef PubMed
20. Goke B, Herrmann C, Goke R, Fehmann HC, Berghofer P, Richter G et al. Intestinal effects of alpha-glucosidase inhibitors: absorption of nutrients and enterohormonal changes. Eur J Clin Invest. 1994; 24 (Suppl): 25-30.
21. Göke B, Fuder H, Wieckhorst G, Theiss U, Stridde E, Littke T, Kleist P, Arnold R, Lücker PW. Voglibose (AO-128) is an efficient alphaglucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion. 1995; 56: 493-501. CrossRef PubMed
22. Holstein A, Beil W. Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions. Expert Opin Drug Metab Toxicol. 2009; 5: 225-241. CrossRef PubMed
23. Kato Y, Narita H, Suzuki H, Okuyama K, Takahashi K-I, Yan KX, et al. Voglibose, an a-glucosidase inhibitor, does not affect the pharmacokinetics and pharmacodynamics of sitagliptin, a DPP-4 inhibitor. 69th Annual Meeting of the American Diabetes Association New Orleans, LA United States 2009; 58: 609-P.
24. He H, Tran P, Yin H, Smith H, Batard Y, Wang L, Einolf H, Gu H, Mangold JB, Fischer V, Howard D. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos. 2009; 37: 536-544. CrossRef PubMed
25. He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet. 2012; 51: 147-162. CrossRef PubMed
26. Moritoh Y, Takeuchi K, Hazama M. Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice. Diabetes Obes Metab. 2010; 12: 224-233. CrossRef PubMed
27. Horikawa Y, Enya M, Iizuka K, Chen GY, Kawachi S-I, Suwa T, Takeda J. Synergistic effect of alpha-glucosidase inhibitors and dipeptidyl peptidase 4 inhibitor treatment. J Diabetes Invest. 2011; 2: 200-203. CrossRef
28. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev. 2002; 18: 430-441. CrossRef PubMed
29. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987; 2: 1300- 1304. CrossRef PubMed
30. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hüfner M, Schmiegel WH. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002; 87: 1239-1246. CrossRef PubMed
31. Shinozaki K, Suzuki M, Ikebuchi M, Hirose J, Hara Y, Harano Y. Improvement of insulin sensitivity and dyslipidemia with a new alphaglucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects. Metabolism. 1996; 45: 731-737. CrossRef PubMed
32. Suzuki M, Hamada I, Odawara M. Vildagliptin as add-on therapy to other oral antidiabetics in Japanese patients with type 2 diabetes. Diabetologia. 2012; 55: S354.